Back to discover
Disease

Stroke, Lacunar

Late-stage therapeutic developmentEmerging research
MeSHStroke, Lacunar
2
Publications
24
Clinical trials
1
Related conditions
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Early neurological deterioration in acute lacunar ischemic stroke: Systematic review of incidence, mechanisms, and prospects for treatment.

Research2024-09-05International journal of stroke : official journal of the International Stroke Society

Cerebral small vessel disease: Recent advances and future directions.

Research2023-01-01International journal of stroke : official journal of the International Stroke Society

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones8View
Results expected 3
Recently completed 2
Other updates 3
Activity timeline8

Clinical trials

14 sponsors · 2 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)

Phase 3 · Active, not recruiting · Wan-Jin Chen

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)

Phase 4 · Active, not recruiting · Seoul National University Hospital

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)

Phase 3 · Active, not recruiting · Capital Medical University

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim
Recently completed

Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Phase 3 · Completed · H. Lundbeck A/S

Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.

Phase 3 · Completed · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)

Phase 3 · Completed · Boehringer Ingelheim

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily

Phase 3 · Completed · Boehringer Ingelheim

EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study

Phase 4 · Completed · Boehringer Ingelheim

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2023–2025
Most influential

Cerebral small vessel disease: Recent advances and future directions.

International journal of stroke : official journal of the International Stroke Society · 2023 · 245 cites

Early neurological deterioration in acute lacunar ischemic stroke: Systematic review of incidence, mechanisms, and prospects for treatment.

International journal of stroke : official journal of the International Stroke Society · 2025 · 19 cites
Recent publications

Early neurological deterioration in acute lacunar ischemic stroke: Systematic review of incidence, mechanisms, and prospects for treatment.

International journal of stroke : official journal of the International Stroke Society · 2025 · 19 cites

Cerebral small vessel disease: Recent advances and future directions.

International journal of stroke : official journal of the International Stroke Society · 2023 · 245 cites
Major themes6
  • Stroke, Lacunar2
  • Cerebral Amyloid Angiopathy1
  • Cerebral Small Vessel Diseases1
  • Cognitive Dysfunction1
  • Ischemic Stroke1
  • Stroke1
Leading journals1
  • International journal of stroke : official journal of the International Stroke Society2
Leading researchers8
  • Markus HS2
  • Dawson J1
  • de Leeuw FE1
  • Doubal F1
  • Freemantle N1
  • Hassan A1
  • Le STN1
  • Mallon D1
Affiliations (unnormalised)6
  • Department of Clinical Neurosciences2
  • Center for Medical Neuroscience1
  • Centre for Clinical Brain Sciences1
  • Comprehensive Clinical Trials Unit1
  • Imperial College London1
  • Leeds General Infirmary1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Cerebral Small Vessel Diseases2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Stroke caused by lacunar infarction or other small vessel diseases of the brain. It features hemiparesis (see PARESIS), hemisensory, or hemisensory motor loss.

Identifiers
MeSHStroke, Lacunar
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.